PEG-PLA copolymers, a depot-injectable polymeric platform created in situ, were utilized to transport BiJ591 (a BsAb targeting CD3+ T cell and prostate-specific membrane antigen (PSMA) on prostate cancer cell) against prostate tumor. Here, FOLH1 is linked to prostate neoplasm.